• Explore /
  • Poster
  • / A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

Abstract Poster

Authors

Ciara O'Sullivan

Ciara Catherine Maria O'Sullivan

NCI/NIH, Bethesda, MD

Ciara Catherine Maria O'Sullivan , Karla V. Ballman , Linda Mackie McCall , Tyler J. Zemla , Anna Weiss , Melissa Mitchell , Victoria Susana Blinder , Nadine M. Tung , William Johnson Irvin Jr., Myounghee Lee , Matthew P. Goetz , William Fraser Symmans , Virginia F. Borges , Ian E. Krop , Ann H. Partridge , Lisa A. Carey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT04457596

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS595)

DOI

10.1200/JCO.2021.39.15_suppl.TPS595

Abstract #

TPS595

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Veronique Debien

First Author: Carey K. Anders

First Author: Tomomi Fujisawa

First Author: Esther Pohl-Rescigno